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CBackground: Skeletal-related events (SREs) occur frequently in pa-
tients with bone metastases as a result of breast (BC) and prostate (PC)
cancers. They increase bothmorbidity andmortality and lead to exten-
sive health-care resource utilization. Methods: Health care resource
tilization by BC/PC patientswith at least one SRE during the preceding
2monthswas assessed through retrospective chart review. SRE-treat-
ent costs were estimated using the Portuguese Ministry of Health
ost database and analyzed using generalized linear models.
esults: This study included 152 patients from nine hospitals. The
ean (SD) annual SRE-treatment cost per patientwas €5963 (€3646) and
5711 (€4347), for BC (n121) and PC (n31) patients, respectively.Mean
ost per single episode ranged between €1485 (radiotherapy) and O
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al So
oi:10.1016/j.jval.2010.11.01413,203 (spinal cord compression). Early onset of bone metastasis (P 
.03) and diagnosis of bonemetastases at or after the occurrence of the
rst SRE (P  0.001) were associated with higher SRE-treatment costs.
onclusion: These results reveal the high hospital SRE-treatment
osts, highlighting the need for early diagnosis and treatment, and
dentify key factors determining the economic value of therapies for
atients with skeletal metastases.
eywords: breast cancer, costs, hospital, prostate cancer, skeletal-
elated events.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Breast (BC) and prostate cancer (PC) are the first- and second-
most diagnosed cancers in their respective genders worldwide
[1]. Together they were estimated to account for more than
630,000 deaths in 2002 [1]. The socioeconomic implications of
BC and PC in developed countries are staggering. Direct treat-
ment costs for PC and BC patients account for approximately
20% of cancer care costs in the United States and Europe, and
indirect costs may contribute to a similar burden, especially in
advanced cancer and the end-of-life settings [2–4]. In 2005, BC
and PC accounted for 16% and 12%, respectively, of cancer
deaths in Portugal [5].
Pathologic fracture (PF), spinal cord compression (SCC), surgery
to bone (SB), radiation therapy to bone (RT), and hypercalcemia of
malignancy (HCM) are common skeletal-related events (SREs) as a
consequence of bonemetastases [6]. Approximately 65% to 75% of
patients withmetastatic BC or PCwill develop skeletal metastases
[6], and 68%of BC and 49%of PCpatientswith bonemetastaseswill
develop one or more SRE in a time frame of 2 years if not treated
with bisphosphonates [7,8].
* Address correspondence to: Jorge Félix, MSc, Av. Humberto Delg
E-mail: jorge.felix@exigoconsultores.com.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.Theonset of SREs is associatedwith significantmorbidity (includ-
ing intractable bone pain, impaired mobility, and decreased health-
related quality of life [QOL]) and decreased survival [9,10]. Pathologic
fractureshavebeenassociatedwithup toa32% increase in the riskof
death in patients with bone metastases from solid tumors [10], and
SREs were associated with a 27% decrease in survival among men
with metastatic PC [11]. Delaying the onset of the first SRE is an im-
portant goal, particularly because of its strong association with cu-
mulative events and poor survival [12].
Costs related to SRE treatment add substantially to the overall
osts of cancer care in patients with metastatic BC or PC, andmay
ccount for more than 50% of their total health care costs [13,14].
etrospective analyses have shown that total treatment costs for
atientswith BCwhodevelop SREsmay beUS$14,000 toUS$22,000
igher than for patients without SREs [15].
Bisphosphonates (BPs) have demonstrated efficacy in reducing
he incidence of SREs in patients with bone metastases. Intrave-
ous BP therapy for the prevention of SREs may reduce the need
or expensive health care, particularly when PF, SCC, and the need
or RT are prevented [16,17].
The costs of SRE treatment versus prevention using BP ther-
py have not been evaluated previously in the context of the
n°33, 2860-021 Alhos Vedros, Portugal.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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500 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 9 9 – 5 0 5Portuguese National Health Service (PNHS). In order to deter-
mine the economic burden of SREs and the economic value of BP
utilization, accurate estimation of treatment costs is important.
The objective of this study was to determine the SRE-related
direct hospital costs and factors determining these costs in Por-
tuguese patients with metastatic BC or PC.
Patients and methods
Study design
This was a multicenter, single-country, retrospective descrip-
tive study. Publicly funded hospitals in Portugal were ranked
using the number of oncology clinical visits in the latest hospi-
tal productivity statistics from the Portuguese Ministry of
Health [18]. Of the 18 PNHS hospitals with oncology and urology
linical services invited, nine agreed to participate. These in-
lude two of the three oncology hospitals and two of the three
niversity hospitals in Portugal. The study protocol was ap-
roved by hospital ethics committees, and informed consent
as obtained from patients before inclusion. The study and
ata collection schemes were designed to avoid influencing fu-
ure treatment decisions for the included patients.
Patients
Adult patients with bone metastases and at least one SRE in
the preceding 12 months were eligible. SREs were defined as
pathologic fracture, spinal cord compression, surgery to bone,
radiation therapy to bone, or hypercalcemia of malignancy at-
tributable by center clinicians to bone metastasis. Initially, pa-
tients were required to be alive when their records were re-
viewed. However, this criterion was later relaxed because it
limited patient accrual. Hence, informed consent could not be
obtained for patients who deceased before their records were
reviewed. Exclusion criteria were diagnosis of other cancer/s as
co-morbidity, pregnancy, and regular follow-up for BC/PC man-
agement in more than one hospital (to avoid the same patient
being enrolled on the study through two different hospitals).
This was important in the context of the Portuguese health sys-
tem because patients may be initially diagnosed in general hos-
pitals and later transferred to oncology hospitals.
Data collection
Cancer diagnosis electronic data sets were used (where available)
to identify eligible patients. In hospitals without such data sets, RT
records and hospital pharmacy records of BP therapy, or paper
clinical records (three hospitals), were used. Data for SRE treat-
ment were obtained from patients’ hospital records. In order to
accommodate inter-hospital variations in the timing of study ap-
proval, a period of 1 year (October 2004 to September 2005) was
Fig. 1 – Data Collection Scheme. Patients eligible for inclusio
in the 12 months prior to study entry. Resource utilization d
treating SREs.allowed for patient enrollment. Therefore, SREs would have oc- Tcurred between October 2003 and September 2005, and resource
utilization refers to this observation period (Fig. 1).
Clinical data included the date of primary cancer diagnosis,
occurrence of first bone metastasis diagnosis, Eastern Coopera-
tive Oncology Group (ECOG) performance status at study entry,
date of first SRE, number of SREs since diagnosis of bone metas-
tasis, and total number of SREs during the observation period.
Health care utilization included frequency and duration of hos-
pitalization, courses of RT and number of days of treatment,
palliative radionuclide therapy (e.g., Sr89 and Sm153), diagnostic
tests, number and type of clinical visits, and all medications
used including BPs.
It is important to note that the data collected pertain to hospi-
tal resource utilization only. Patient-reported costs (e.g., over-the-
counter analgesics, medical services outside the hospital setting,
transportation) and indirect costs related to the loss of productiv-
ity or premature death were not included. Because the participat-
ing hospitals all belong to the publicly funded PNHS, estimated
treatment costs may be lower than costs in other (private) hospi-
tals.
Cost estimation
Investigators were not granted direct access to hospital account-
ing systems. Therefore, costs for procedures such as hospitaliza-
tion, RT, diagnostics, and clinical visits, were estimated using the
PNHS price list, which is used by publicly funded hospitals to price
services provided to third parties such as private insurers or the
Portuguese Civil Servants Health System [19]. Prices for hospital
drugs were obtained from the Institute for Financial Management
and Informatics (IGIF) price catalog (2003–2005) used by hospitals
as a maximum reference price list for acquisition of medications.
Resource utilization and costs considered were limited to those
related to the treatment of SREs.
Data analysis/modeling
Differences in age, time from cancer diagnosis to bonemetastasis,
and frequency of diagnosis of bone metastases after SRE onset
were assessed using t test, log-rank test, and chi-square test, re-
spectively. The 95% confidence interval formedian 12-month SRE-
related costs was estimated using the binomial exact method.
Non-parametric Wilcox and Kruskal-Wallis tests were used to as-
sess differences in total SRE-treatment cost according to patient
characteristics. The costs of SRE hospital treatment weremodeled
assuming two different dependent variables. For the total sample,
total SRE-treatment cost was used as the dependent variable. For
the BC patients’ sample, SRE-treatment cost excluding the cost of
the BPs and its administration was also used as the dependent
variable in order to include the type of BP used as a covariate in the
model. Generalized linearmodels (GLMs)with gammadistribution
and logarithm link function were fitted to estimate the effects of
independent variables in the expected SRE treatment costs [20].
d undergone treatment for > 1 skeletal-related event (SRE)
g these 12 months was used to determine the cost ofn ha
urinhese models allow the measurement of the association be-
.501V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 9 9 – 5 0 5tween independent variables and SRE cost through the expo-
nential of regression coefficients (e), while controlling for pa-
tients’ and clinical characteristics. Independent variables
approaching the statistical significance level of 0.10 in the bi-
variate analysis were included in multivariate models. Stan-
dardized deviance residuals and likelihood ratio test were used
for model diagnostics. All statistical analyses were performed
using R software version 2.8 [21].
Results
Patient demographics and clinical characteristics
The study enrolled 152 patients with bone metastases from BC
(n 121) or PC (n 31). All patients had experienced at least 1 SRE
during the 12-month observation period. Mean (SD) age at diagno-
sis of bone metastasis was 58.3 (13) years (Table 1). Overall, com-
pared with BC, patients with PC were older (P  0.001) and had a
longer median duration from cancer diagnosis to diagnosis of
bone metastasis (38 vs. 5 months, P  0.01), a higher frequency of
bonemetastasis diagnosis after the onset of SREs, (17% vs. 7%, P
0.01), and worse ECOG performance status (Table 1).
Over the 12-month observation period, 183 SREs were regis-
tered, 146 (79.8%) in patients with BC. The mean number of SREs
per patient was 1.2 (range: 1 to 3). Radiotherapy to bone was the
most frequent SRE (69.9%). Among patients for whom BP utiliza-
tion data were available (n 139, 13missing), 65.4% received zole-
Table 1 – Patients’ characteristics.
(n 
Status at chart review (alive/dead), n* 9
Bone metastases
Age at dx, mean yrs  SD 58.3
Time from cancer dx, median mo [95% CI] 34.5 [1
After onset of SREs (yes/no), n* 20
SRE, n (%)†
Any 183
Surgery 4
Spinal cord compression 14
Pathologic fracture 27
Radiation therapy to bone 128
Hypercalcemia of malignancy 10
ECOG PS, n (%)‡
0 17
1 34
2 14
3 8
4 7
Bisphosphonate treatment, n (%)§
ZOL 91
PAM 30
PAM ¡ ZOL 4
Oral BP 5
No BP 9
Unknown 13
BC, breast cancer; BP, bisphosphonate; dx, diagnosis; ECOG PS, East
pamidronate; PAM ¡ ZOL, patients initially treated with PAM but s
standard deviation; SRE, skeletal-related event; yrs, years; ZOL, zoled
* Numbers of patients do not equal total sample because of missing
† Percentage of total SREs (e.g., 183  100% for the total sample).
‡ ECOG PS data were collected only for patients alive at study initiat
§ Percentage of patients for whom BP utilization data were availabledronic acid (ZOL), 21.6% received pamidronate (PAM); 2.9% initi-ated therapy with PAM and later switched to ZOL during the study
period, 3.6% received oral BPs, and the remainder (6.5%) were not
treated with BPs. At the time of data collection, 98 patients were
alive, of whom the majority had a good ECOG performance status
(Table 1).
Table 2 – Resource utilization.
N Mean SD
Radioisotopes 5 1.0 —
Clinic visits 152 2.8 3.0
Hospitalization (duration in days) 38 19.7 13.7
Diagnostics* 42 22.0 52
Radiotherapy 118 1.1 0.36
Sessions per treatment 8.38 3.25
Medications†
Analgesic‡ 20 1.35 0.79
IV BP (duration in days) 121 263 63
Oral BP (duration in days) 5 333 34
BP, bisphosphonates; IV, intravenous; SD, standard deviation.
* Refers to the number of different diagnostics procedures, including
blood tests, x-ray, computed tomography, magnetic resonance im-
aging, scintigraphy, bone densitometry, and bone biopsy.
† Excluding chemotherapyandhormonal therapy for primary cancer.
)
BC
(n  121)
PC
(n  31)
76/39 22/6
.0 56.8 13.2 65.3  9.1
9.7] 38.3 [23.9; 57.2] 4.8 [2.1; 49.7]
18/102 2/28
142 (100) 41 (100)
3 (2.1) 1 (2.7)
9 (6.2) 5 (13.5)
) 20 (13.7) 7 (18.9)
) 105 (71.9) 23 (62.2)
9 (6.2) 1 (2.7)
) 15 (24.6) 2 (10.5)
) 28 (45.9) 6 (31.6)
) 11 (18.0) 3 (15.8)
) 5 (8.2) 3 (15.8)
2 (3.3) 5 (26.3)
) 77 (65.8) 14 (63.6)
) 30 (25.6) 0
1 (0.9) 3 (13.7)
5 (4.3) 0
4 (3.4) 5 (22.7)
4 (3.3) 9 (29.0)
ooperative Oncology Group performance status; mo, months; PAM,
ed to ZOL during the observation period; PC, prostate cancer; SD,
acid.
for 9 patients.
ata were not available for 18 patients.All
152
8/45
 13
5.9; 4
/130
(100)
(2.2)
(7.7)
(14.8
(69.9
(5.5)
(21.2
(42.5
(17.5
(10.0
(8.8)
(65.4
(21.6
(2.9)
(3.6)
(6.5)
(8.6)
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In the total sample (BCPC), 38 (25%) patients were hospitalized
within the 12-month observation period of the study. The mean
length of stay was 19.7 days (SD  13.7 days; min-max [1–45]). On
average (SD), each patient (n 118) using RT was submitted to 1.1
(0.36) treatments, consisting of 8.4 (3.3) RT sessions. Radiotherapy
with Sm153 (radioisotope) was used in only five patients. Overall,
86% and 3.3% of patients received IV and oral BPs, with mean
treatment duration of 263 and 333 days, respectively (Table 2).
The estimated mean 12-month SRE-related costs per patient
were €5963 (median €5105, 95%CI [€4846; €5,321]) and €5711 (me-
dian  €4723, 95%CI [€3467; €6052]) for patients with BC and PC,
respectively. In BC patients the costs ofmedications (including BPs
but excluding chemo/hormonal treatment) accounted for approx-
imately 50.8% of the total, whereas hospitalization accounted for
the largest proportion of costs (38.8%) in PC patients. Utilization of
these two resources together accounted for approximately 70% of
total SRE costs in both patient groups (Table 3). The average cost
per type of SRE was also examined (Fig. 2). Spinal cord compres-
sionwas themost expensive (€13,203), whereas RT to bone had the
lowest cost (€1485) per episode. Bivariate analyses revealed no dif-
Table 3 – SRE treatment costs by type of resource.
Breast
Mean, € SD Perce
Radioisotopes 14 153
Clinic visits 36 101
Hospitalization 1312 3056
Diagnostics 103 370
Radiotherapy 1467 882
Medications* 3031 1290
Total, mean  SD €5963  3646
SD, standard deviation; SRE, skeletal-related event.
All monetary units are given in Euros (€).
* Including bisphosphonates, but excluding chemotherapy and horm
Fig. 2 – Mean Treatment Cost by SRE Type. Mean cost of trea
determined using hospital records of direct treatment-costs
reported costs).ferences in total SRE costs by cancer type (P 0.43), patient status
at the time of chart review (alive or dead; P  0.11), or age at bone
metastasis diagnosis (P 0.71). Diagnosis of bone metastasis at or
after the onset of SREs was associated with significantly higher
costs compared to diagnosis prior to the onset of SREs (mean 
€10,363 vs. €5280; P  0.01). Other factors influencing total cost of
SRE treatment were poor ECOG performance status
(P  0.01) and type of BP used (P  0.01). On average, higher costs
were associated with patients started on PAM and then switched
to ZOL (€11,673) compared with those receiving PAM only (€6767),
ZOL only (€681) or no BPs at all (€4757). The bivariate analysis of
SRE total costs showed similar results in the “BC patients” subset,
whereas the only significant variable in the PC subset was the type
of BP.
Modeling of SRE-treatment costs
In the total sample, the expected total SRE cost was €5924 for the
reference patient (BC) (Table 4). The independent multiplicative
effect of the reported covariates can be found from the exponen-
tial coefficient relative to the constant. Thus, with all other vari-
Treatment costs
Prostate
total Mean, € SD Percent of total
218 575 3.8
27 53 0.5
2213 3993 38.7
83 196 1.5
1402 1148 24.5
1768 1668 31.0
€5711  4346
therapy.
nt for each type of skeletal-related event (SRE) was
luding chemo/hormonal therapy for cancer and patient-nt of
0.2
0.6
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503V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 9 9 – 5 0 5ables kept constant, diagnosis of bone metastasis after the onset
of SREs was associated with a 56% increase in total SRE-treatment
costs (P  0.002, total cost  €9241). Each 12-month increment in
ime from cancer diagnosis to diagnosis of bone metastasis was
ssociated with a 2.4% decrease in SRE treatment costs (P 0.041).
There were no PAM-treated patients in our PC sample. There-
ore, modeling SRE treatment costs using the type of IV BP as co-
ariate was limited to the breast cancer subset. Such modeling of
RE-related costs with and without cost of the BP (Table 5) helps
est the hypothesis that drugs with higher acquisition costs may
e cost-effective if their use results in subsequent treatment cost
ffsets and/or improvements in clinical outcomes.
In modeling of SRE-related costs in BC patients, bone metas-
asis diagnosis after the onset of SREs was associated with a 61%
ncrease in total SRE treatment costs (P  0.001), and shorter
ime between cancer diagnosis and bone metastasis was asso-
iated with a 2.1% increment in cost per year decrease. In con-
rast to the overall sample, SRE-related treatment costs for pa-
ients with BC who were alive at the time of data collection were
2% higher than for patients who died before data collection
P  0.031). After controlling for all other variables, PAM treatment
as associatedwith a nonsignificant numeric cost increment of 12%
ersus ZOL despite the lower procurement cost of PAM. Thus, there
ere no significant differences in overall treatment costs between
he PAM-treated and ZOL-treated groups. However, patientswho re-
eived PAM experienced significantly more SREs compared with pa-
ients receiving ZOL (1.3 vs. 1.1; P 0.04).
A secondary hypothesis-generating analysis excluding the
cost of BP therapy in the BC group of our retrospective, obser-
vational study estimated an 84% (95%CI [27%; 167%]) increment
in the costs of resource use among patients receiving PAM ver-
sus ZOL (Table 5). Similar to outcomes from themodel including
Table 4 – GLM modeling of total SRE treatment costs: total
Prostate cancer*
Alive at data collection
Age at bone metastasis, years
Time between cancer diagnosis and bone metastasis, years
Bone metastasis diagnosis after SRE
Constant
, regression coefficient; CI, confidence interval; e, exponential of the
SRE, skeletal-related event.
* Reference category: Breast cancer patients
Table 5 – GLM modeling of SRE treatment costs: breast can
Total cost
 SE P value
Alive at data collection 0.199 0.092 0.031
Age at bone metastasis, years 0.001 0.003 0.867
Time between cancer diagnosis and
bone metastasis, years
0.022 0.01 0.036
Bone metastasis diagnosis after SRE 0.476 0.126 0.001
PAM* 0.116 0.099 0.241
Oral BP* 1.493 0.214 0.001
Without BP* 0.513 0.249 0.039
Constant 8.581 0.212 0.001 5
, regression coefficient; BP, bisphosphonate; CI, confidence interval;
to the reference category); GLM, generalized linear model; PAM, pam
* Reference category: zoledronic acid treatment.BP costs, diagnosis of bone metastasis at or after SRE onset was
associated with a significant 180% increase in treatment costs
(P  0.001), whereas longer time between diagnosis of cancer
and the development of bone metastasis was associated with a
significant 5% reduction per year in SRE-treatment costs (ex-
cluding the cost of BPs).
Discussion
To our knowledge, this study is one of the few estimating SRE treat-
ment costs in patients being treated in day-to-day clinical practice,
and applying statistical techniques for SRE costmodelingwhile con-
trolling fordifferences in thesamplepopulationpotentially related to
observational retrospective data collection. As with all retrospective
studies, however, our studydesignhas certain limitations thatmight
influence the results.
Our study was dependent on hospitals’ willingness to partici-
pate. Therefore, both the hospitals and patients are convenience
samples. No formal assessment wasmade to determine the study
sample representativeness because raw statistics were not avail-
able from public hospitals in Portugal. If we consider, however,
medical oncology visits as proxy for hospital activity (i.e., reflect-
ing the number of oncology patients treated in each hospital), then
our sample can be considered reasonably representative. It in-
cluded two thirds of all oncology and university hospitals, ac-
counting for 52% and 68% of the medical oncology visits in such
institutions, respectively. The remaining were a mixture of major
urban-area hospitals (central) and smaller size hospitals, far from
large metropolitan areas (responsible for 32% of the oncology vis-
its nationwide) [18]. The latter may be underrepresented com-
pared with the former. Nationwide, the nine hospitals partici-
le (n = 107).
SE P value e (95% CI)
9 0.170 0.163 1.27 (0.91; 1.77)
7 0.104 0.266 1.12 (0.92; 1.38)
1 0.004 0.728 1.00 (0.99; 1.01)
4 0.012 0.041 0.98 (0.95; 1.00)
6 0.140 0.002 1.56 (1.19; 2.06)
7 0.235 0.001 5924 (3736; 9392)
ession coefficient; GLM, generalized linear model; SE, standard error;
atient sample (n = 97).
Excluding BP costs
(95% CI)  SE P value e (95% CI)
(1.02; 1.46) 0.156 0.179 0.388 1.17 (0.82; 1.66)
(0.99; 1.01) 0.000 0.006 0.942 1.00 (0.99; 1.01)
(0.96; 1.00) 0.048 0.002 0.031 0.95 (0.91; 0.99)
(1.26; 2.06) 1.027 0.243 0.001 2.8 (1.74; 4.49)
(0.93; 1.36) 0.61 0.19 0.002 1.84 (1.27; 2.67)
(0.15; 0.34) 0.505 0.413 0.225 0.6 (0.27; 1.36)
(0.37; 0.98) 0.653 0.478 0.175 1.92 (0.75; 4.90)
(3519; 8072) 7.583 0.422 0.001 1964 (859; 4491)
ponential of the regression coefficient (multiplicative effect relative
ate; SE, standard error; SRE, skeletal-related event.samp

0.23
0.11
0.00
0.02
0.44
8.68
regrcer p
s
e
1.22
1.00
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1.61
1.12
0.22
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504 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 9 9 – 5 0 5pating in our study accounted for approximately 43% of all
oncology visits to PNHS hospitals in 2005.
The number and characteristics of patients recruited from
each hospital were physicians’ decisions based on study protocol
inclusion and exclusion criteria. Therefore, theremight have been
some selection bias, which could not be controlled for by research-
ers. Few hospitals had fully electronic clinical records. Another
possible source of bias relates to inter-institution differences in
how clinical records were maintained, potentially resulting in im-
balanced registration of resource use. The use of regression mod-
els including treatment center as a covariate may help minimize
these potential biases; however, this was not possible without re-
ducing the number of hospitals included in the statistical analysis
and compromising overall sample size (five hospitals included
contributed  10 patients each). Also, there were some important
linical parameters that were not recorded, and therefore could
ot be included in themodel, e.g., non-osseousmetastatic disease
nd bone pain. Thus, these caveats must be kept in mind when
nterpreting our results.
The 1-year SRE treatment costs estimated in our study are re-
arkably similar to the costs of SRE treatment reported in other
tudies conducted in Europe using either hospital records data
14] or even cost analysis derived from clinical trials [22]. They
are somewhat lower than those reported by researchers in the
United States using insurance claims databases for cost analy-
sis [15,16,23]. For example, in a retrospective analysis from a com-
munity and a university hospital in The Netherlands based on
chart review of 31 patients with prostate cancer metastatic to
bone, it was found that the average total cost of care was around
€13,000, of which approximately 50%was attributable to the treat-
ment of SREs [14]. In another single-institution study, the total cost
incurred by patients with malignant osteolytic bone disease (60%
breast cancer, 21% multiple myeloma, and 19% other tumors)
amounted to an average of €12,060 with 48% of this cost being
incurred during the BP-treatment phase [22]. Two studies from the
USA, based on insurance claims data and aiming to estimate the
cost of treating SREs in metastatic breast [15] and prostate cancer
[16], reported a 1-year SRE mean treatment cost of US$13,940 and
US$12,469, respectively. These costs are roughly equivalent to
€9791 and €8758 (1 EURO  1.4238 USD, European Central Bank,
June 2, 2009). The differences in SRE costs compared with those
from our studymay be related to a different mix of SREs as well as
to differences in unit costs of health care procedures on both sides
of the Atlantic. Comparedwith the BC population studied by Delea
et al. [15], the BC patients in our study received more RT (88% vs.
56%) and had fewer PF (15% vs. 34%). On the other hand, the PC
patients experienced an identical proportion of episodes of HCM
(0.3% vs. 0.3%), more SCC (13% vs. 8.5%) and similar PF rates (23%
vs. 23.4%), versus the study by Lage et al. [16].
Our observations of increased SRE incidence in PAM-treated
patients (vs. ZOL) are also consistent with reported outcomes in
the BC stratum from the phase III head-to-head trial of PAMversus
ZOL in patients with bone lesions from multiple myeloma or BC
[24], as well as the Cochrane meta-analysis of placebo-controlled
trials of BPs in metastatic BC [25]. In view of the higher SRE inci-
dence in PAM- versus ZOL-treated patients in our study, the in-
creased treatment costs (excluding BPs) in the PAM group are not
surprising.
In contrast to our results, other studies have reported similar
efficacy as well as cost-effectiveness for PAM versus ZOL in the
metastatic BC and PC settings [26–29]. However, in analyses that
rely on clinical trial data to estimate cost-effectiveness [26,28,29],
the applicability to the real-world setting may be confounded by
factors such as higher-than-normal rates of persistencewith ther-
apy (in the case of oral BPs).
Also in the context of our study, becausewe limited our patient
sample to a small number of tertiary hospitals and a relatively dshort duration for accrual, variables such as concomitant chemo-
therapy and diagnostic practicesmay be better controlled for com-
pared with analyses based on clinical trial data. In routine clinical
practice, persistence rates with daily oral BPs are very low (35%
over 6 months in patients with bone metastases) [30]. Therefore,
calculations of cost-effectiveness of oral therapies based on SRE-
prevention outcomes in clinical trials may substantially overesti-
mate true efficacy and cost-effectiveness in normal practice. On
the other hand, interpretation of the results from our study is
complicated by the unknown effects of retrospective data collec-
tion and lack of randomization. Therefore, our findings lack addi-
tional validation from prospective pragmatic trials.
Modeling SRE treatment costs using multivariate analysis
(GLM) is particularly useful to account for patients and clinical
differences arising from the study design. For example, in the
modeling analysis of the total sample, each additional year be-
tween diagnosis of cancer and development of bone metastasis
was independently associated with a 2.4% decrease in SRE costs,
after controlling for the other covariates present in the model. On
the other hand, diagnosis of bone metastasis at or after SRE onset
was associated with a 19% to 106% increase in treatment costs,
suggesting that the late diagnosis of bone metastasis may lead to
more frequent or more severe SREs, hence increasing resource
utilization and costs.
Modeling SRE treatment costs including and excluding the
costs of BPs allows for an alternative perspective on the cost dif-
ferences in utilization of other health care resources, such as hos-
pitalizations, diagnostics, and non-drug treatments (e.g., RT), all of
whichmay vary substantially depending on the BP used to prevent
or treat SREs. This perspective is appealing in economic terms
because it can reveal different patterns of resource utilization and
costs in relation to differences in effectiveness of different agents.
In the BC subset, if overall resource use is considered, no differ-
ence was observed between ZOL and PAM. However, the higher
SRE incidence in PAM-treated patients, combined with the overall
high cost of treating SREs, suggests that increased acquisition
costs for more expensive agents might be offset by improved ef-
fectiveness. Prospective, randomized trials comparing these two
BPs in a real-world setting are needed to directly evaluate the dif-
ferences between costs and health outcomeswith the use of these
two BPs inmetastatic BC. Such a pragmatic studymay also include
data collection on bottom-up direct and indirect costs.
The cost estimates for our sample of patients underestimate
the true societal costs of SREs for three reasons: 1) no assessment
of private and out-of-hospital resource utilization; 2) the retro-
spective nature of the study design; and 3) no inclusion of indirect
cost.
Our study did not assess private and out-of-hospital resource
utilization; therefore, costs incurred by patients and their families
are not taken into account. These costsmay be important because
in contemporary health care management there is a trend to re-
strict expensive hospital care to strictly necessary aspects, and to
discharge patients to ambulatory care as soon as possible [31,32].
Other studies found that these costs can represent a substantial
burden [17] and can outweigh inpatient costs [16]. In the context of
he Portuguese health care system, private expenditure on health
are represents about 30% of the total health expenses [33].
The problems related to retrospective data collection fromclin-
cal records were more evident in missing data from clinical visits
nd diagnostics. In both groups of patients, costs for clinical visits
epresented less than 1% of the total, and diagnostics represented
ess than 2%. These are extremely low values comparedwith other
tudies wherein these resources contributed to approximately
5% of total costs and up to 43% of the additional costs associated
ith SREs [14,15].
The inclusion of patients who had already died at the time ofata review (approximately one-third of the patients in our study)
a
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505V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 9 9 – 5 0 5may also have influenced SRE treatment costs. Close proximity to
death has been associated with higher costs of care [34,35], espe-
cially for cancer patients [36]. However, in our study no significant
differences in SRE treatment costs were observed based on sur-
vival at the time data collection was initiated.
Unlikeother studies thatattempt toaccount for indirect costsand
generate an estimate of total costs (an estimate that inherently has
substantial variability), the costs in thepresent studywere calculated
by actual resource utilization and cost assigned by the Portuguese
Ministry of Health. The exclusion of indirect costs in this analysis
is not attempt to minimize their importance. Indirect costs can
impose a large burden on society. Nonetheless, their accurate
measurement is difficult and prone to considerable subjective
variation [37]. Inclusion of only direct costs minimizes variability,
llowing better comparison of the costs for each SRE and for mod-
ling to determine factors that influence SRE-treatment costs.
Conclusion
This observational, retrospective study analyzed resource use re-
lated to SRE from a Portuguese hospital perspective, and identified
several factors that may influence the cost of treating and/or pre-
venting SREs. Moreover, these results underscore the importance
of timely diagnosis and treatment of bone metastases, and high-
light the need for a pragmatic prospective evaluation of the most
cost-effective BP treatment for patients with skeletal metastases
from BC.
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